SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lee DY, Hayes JJ, Pruss D, Wolffe AP 1993 A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72: 7384.
  • 2
    Hassig CA, Schreiber SL 1997 Nuclear histone acetylases and deacetylases and transcriptional regulation: HATS off to HDACs. Curr Opin Chem Biol 1: 300308.
  • 3
    Grunstein M 1997 Histone acetylation in chromatin structure and transcription. Nature 389: 349352.
  • 4
    Gray SG, Ekstrom TJ 2001 The human histone deacetylase family. Exp Cell Res 262: 7583.
  • 5
    Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, Sung CM, Liu R, Winkler J 2000 Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 275: 1525415264.
  • 6
    Gao L, Cueto MA, Asselbergs F, Atadja P 2002 Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 2574825755.
  • 7
    Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X 2002 Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Molec Cell Biol 22: 79827992.
  • 8
    Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th'ng J, Han J, Yang XJ 1999 HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Molec Cell Biol 19: 78167827.
  • 9
    Bertos NR, Wang AH, Yang XJ 2001 Class II histone deacetylases: Structure, function, and regulation. Biochem Cell Biol 79: 243252.
  • 10
    Guardiola AR, Yao TP 2002 Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277: 33503356.
  • 11
    Grozinger CM, Hassig CA, Schreiber SL 1999 Three proteins define a class of human histone deacetylases related to yeast HDa1p. Proc Natl Acad Sci USA 96: 48684873.
  • 12
    Grozinger CM, Schreiber SL 2000 Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14–3–3-dependent cellular localization. Proc Natl Acad Sci USA 97: 78357840.
  • 13
    Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M, Khochbin S 2000 Active maintenance of mHDA2/mHDAC6 histone deacetylase in the cytoplasm. Curr Biol 10: 747749.
  • 14
    North BJ, Marshall BL, Borra MT, Denu JM, Verdin E 2003 The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437444.
  • 15
    Onyango P, Celic I, MaCaffery JM, Boeke JD, Feinberg AP 2002 SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to the mitochondria. Proc Natl Acad Sci USA 99: 1365313658.
  • 16
    Yoshida M, Kijima M, Akita M, Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 1717417179.
  • 17
    Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H 2001 Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61: 44594466.
  • 18
    Candido EP, Reeves R, Davie JR 1978 Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14: 105113.
  • 19
    Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O 1999 A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 45924597.
  • 20
    Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG 1999 Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 12521258.
  • 21
    Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG 2000 Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 20692083.
  • 22
    Somech R, Izraeli S, Simon J 2004 Histone deacetylase inhibitors—a new tool to treat cancer. Cancer Treat Rev 30: 461472.
  • 23
    Chung Y, Lee MY, Wang AJ, Yao LF 2003 A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8: 707717.
  • 24
    Antos C, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN 2003 Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278: 2893028937.
  • 25
    Iwami K, Moriyama T 1993 Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 25: 16311635.
  • 26
    Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T 2004 Trichostatin A activates the osteopontin gene promoter through AP1 site. Biophys Res 315: 959963.
  • 27
    Schroeder TM, Kahler RA, Li X, Westendorf JJ 2004 Histone deacetylase 3 interacts with Runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279: 4199842007.
  • 28
    Pockwinse S, Wilming LG, Conlon DM, Stein GS, Lian JB 1992 Expression of cell growth and bone specific genes at single cell resolution during growth and development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49: 310323.
  • 29
    McCauley L, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT 1996 PTH/PThrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem 61: 638647.
  • 30
    Gopalakrishnan R, Ouyang H, Somerman MJ, McCauley LK, Franceschi RT 2001 Matrix gamma-carboxyglutamic acid protein is a key regulator of PTH-mediated inhibition of mineralization in MC3T3-E1 osteoblast-like cells. Endocrinology 142: 43794388.
  • 31
    Traianedes K, Dallas MR, Garrett IR, Mundy GR, Bonewald LF 1998 5-lipoxygenase metabolites inhibit bone formation in vivo. Endocrinology 139: 31783184.
  • 32
    Garrett IR 2003 Assessing bone formation using mouse calvarial organ cultures. In: HelfrichM, RalstonSH (eds.) Methods in Molecular Medicine: Bone Research Protocols, vol. 80. Humana Press, Totowa, NJ, USA, pp. 183198.
  • 33
    Villar-Garea AAME 2004 Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int J Biochem 112: 171178.
  • 34
    Vega R, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karenty G, Olson EN 2004 Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119: 555566.
  • 35
    Kang JS, Alliston T, Delston R, Derynck R 2005 Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 24: 25432555.
  • 36
    Yoshida M, Kijima M, Akita M, Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 1717417179.
  • 37
    Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH 2004 Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA 101: 1665916664.
  • 38
    Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A 2000 Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 6: 43344342.
  • 39
    Westendorf JJ, Kahler RA, Schroeder TM 2004 Wnt signaling in osteoblasts and bone diseases. Gene 341: 1939.
  • 40
    Phiel C, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 3673436741.
  • 41
    Levy L, Wei Y, Labalette C, Wu Y, Renard CA, Buendia MA, Neuveut C 2004 Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 24: 34043414.
  • 42
    Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS 2004 Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 10791086.
  • 43
    Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M 2003 Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720728.
  • 44
    Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K 2001 Decreased bone mass and turnover with valproate therapy in adults with epilepsy. Neurology 57: 445449.
  • 45
    Oner N, Kaya M, Karasalihoglu S, Karaca H, Celtik C, Tutunculer F 2004 Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 40: 470473.
  • 46
    Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A 2004 The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50: 9397.
  • 47
    Vestergaard P, Rejnmark L, Mosekilde L 2004 Fracture risk associated with use of antiepileptic drugs. Epilepsia 45: 13301337.
  • 48
    Guo C, Ronen GM, Atkinson SA 2001 Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42: 11411147.
  • 49
    Coleman R 1997 Skeletal complications of malignancy. Cancer 80: 15881594.
  • 50
    Sambucetti L, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D 1999 Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 49404947.
  • 51
    Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T 2003 p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 554: 347350.
  • 52
    Zhang Y, Jung M, Dritschilo A, Jung M 2004 Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161: 667674.
  • 53
    Camphausen K, Scott T, Sproull M, Tofilon PJ 2004 Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10: 60666071.
  • 54
    Rahman M, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O 2003 Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101: 34513459.